10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2022 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 6, 2023) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash flows from operating activities: | |||
| Net income | $ 4,338,400 | 8,075,300 | 3,513,200 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 341,400 | 286,200 | 235,900 |
| Stock-based compensation expense | 725,000 | 601,700 | 432,000 |
| Losses (gains) on marketable and other securities, net | 36,800 | (387,000) | (221,800) |
| Other non-cash items, net | 368,000 | 568,700 | 86,800 |
| Deferred income taxes | (746,400) | (147,100) | 75,600 |
| Acquired in-process research and development in connection with asset acquisition | 195,000 | 0 | 0 |
| Changes in assets and liabilities: | |||
| Decrease (increase) in accounts receivable | 707,800 | (1,927,400) | (1,356,100) |
| Increase in inventories | (696,500) | (494,300) | (529,400) |
| (Increase) decrease in prepaid expenses and other assets | (148,600) | (240,700) | 114,900 |
| Increase (decrease) in deferred revenue | 32,400 | (120,200) | 148,100 |
| (Decrease) increase in accounts payable, accrued expenses, and other liabilities | (138,400) | 866,100 | 118,900 |
| Total adjustments | 676,500 | (994,000) | (895,100) |
| Net cash provided by operating activities | 5,014,900 | 7,081,300 | 2,618,100 |
| Cash flows from investing activities: | |||
| Purchases of marketable and other securities | (7,487,900) | (7,048,100) | (3,241,000) |
| Sales or maturities of marketable and other securities | 5,550,500 | 2,215,300 | 3,785,000 |
| Capital expenditures | (590,100) | (551,900) | (614,600) |
| Payments for Libtayo intangible asset | (1,026,800) | 0 | 0 |
| Asset acquisition, net of cash acquired | (230,300) | 0 | 0 |
| Net cash used in investing activities | (3,784,600) | (5,384,700) | (70,600) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of Common Stock | 1,519,500 | 1,672,300 | 2,575,200 |
| Payments in connection with Common Stock tendered for employee tax obligations | (445,700) | (1,032,700) | (680,800) |
| Repurchases of Common Stock | (2,082,800) | (1,645,400) | (5,846,800) |
| Proceeds from issuance of long-term debt | 0 | 0 | 1,981,900 |
| Proceeds from bridge loan facility | 0 | 0 | 1,500,000 |
| Repayment of bridge loan facility | 0 | 0 | (1,500,000) |
| Net cash used in financing activities | (1,009,000) | (1,005,800) | (1,970,500) |
| Net increase in cash, cash equivalents, and restricted cash | 221,300 | 690,800 | 577,000 |
| Cash, cash equivalents, and restricted cash at beginning of period | 2,898,100 | 2,207,300 | |
| Cash, cash equivalents, and restricted cash at end of period | 3,119,400 | 2,898,100 | 2,207,300 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest (net of amounts capitalized) | 53,700 | 55,800 | 23,200 |
| Cash paid for income taxes | 1,502,400 | 1,218,400 | 188,100 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |